|
Market Closed -
Nasdaq
16:00:00 2026-10-14 EDT
|
5-day change | 1st Jan Change | ||
| 3.380 USD | -2.59% |
|
-8.65% | +12.29% |
| 09-01 | Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target | MT |
| 08-06 | Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib | DJ |
| Market Cap | 511M 459M 429M 388M 729M 48.61B 734M 5.14B 2.01B 25.23B 1.92B 1.88B 81.14B | P/E 2026 * |
-5.23x | P/E 2027 * | -4.3x |
|---|---|---|---|---|---|
| Enterprise Value | 348M 313M 292M 265M 497M 33.12B 500M 3.5B 1.37B 17.19B 1.31B 1.28B 55.29B | EV / Sales 2026 * |
54.9x | EV / Sales 2027 * | 68.2x |
| Free-Float |
97.82% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ACRS | Delayed | |
CBOE
| ACRS | Real-time | |
|
Tradegate
| 8AT | Real-time | |
|
Boerse Muenchen
| 8AT | Real-time | |
|
Deutsche Boerse AG
| 8AT | Delayed | |
|
Börse Stuttgart
| 8AT | Delayed |
Last Transcript: Aclaris Therapeutics, Inc.
| 1 day | -2.59% | ||
| 1 week | -8.65% | ||
| Current month | -35.74% | ||
| 1 month | -36.47% | ||
| 3 months | -38.55% | ||
| 6 months | -13.33% | ||
| Current year | +12.29% |
| 1 week | 3.18 |  | 3.94 |
| 1 month | 3.18 | | 5.76 |
| Current year | 2.49 | | 6.6 |
| 1 year | 1.83 | | 6.6 |
| 3 years | 0.59 | | 6.6 |
| 5 years | 0.59 | | 18.96 |
| 10 years | 0.59 | | 33.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Neal Walker
CEO | Chief Executive Officer | 56 | 2024-01-16 |
Hugh Davis
PSD | President | 67 | 2024-11-17 |
Kevin Balthaser
DFI | Director of Finance/CFO | 39 | 2022-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Neal Walker
CHM | Chairman | 56 | 2022-12-31 |
Anand Mehra
BRD | Director/Board Member | 50 | 2014-08-31 |
| Director/Board Member | 59 | 2016-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/1/26 | Exercice | Chief Technology Officer | 85,135 | 0.0610% | ||
| 6/4/26 | Aisling Capital Management LP
| Other | Company | 0 | 0% | - |
| 5/1/26 | Exercice | Chief Technology Officer | 82,080 | 0.0681% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.59% | -8.65% | +76.96% | -36.47% | 511M | |
| -2.01% | -7.86% | +54.60% | +70.97% | 70.44B | |
| +3.84% | -10.61% | +6.97% | +57.43% | 50.31B | |
| +3.35% | +1.60% | +10.58% | +40.01% | 47.51B | |
| +0.51% | +0.78% | +28.58% | +31.43% | 42.91B | |
| +2.70% | -3.18% | +296.96% | +547.01% | 40.39B | |
| +0.69% | -3.11% | +7.48% | +96.59% | 39.69B | |
| +0.06% | -1.43% | +10.47% | +43.27% | 30.59B | |
| -2.95% | -14.09% | +37.94% | +1.30% | 26.8B | |
| -0.39% | -7.39% | -13.33% | -14.40% | 22.36B | |
| Average | +0.32% | -5.64% | +51.72% | +83.71% | 37.15B | |
| Weighted average by Cap. | +0.76% | -5.44% | +51.93% | +102.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.34M 5.7M 5.32M 4.82M 9.05M 603M 9.11M 63.82M 24.92M 313M 23.8M 23.28M 1.01B | 5.34M 4.8M 4.48M 4.06M 7.62M 508M 7.67M 53.75M 20.99M 264M 20.04M 19.61M 848M |
| Net income | -90.33M -81.22M -75.79M -68.69M -129M -8.6B -130M -910M -355M -4.46B -339M -332M -14.35B | -112M -101M -94.26M -85.43M -160M -10.69B -161M -1.13B -442M -5.55B -422M -413M -17.85B |
| Net Debt | -163M -146M -137M -124M -232M -15.49B -234M -1.64B -640M -8.04B -611M -598M -25.85B | -147M -132M -123M -111M -209M -13.95B -211M -1.48B -576M -7.24B -550M -538M -23.28B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-14 | US$3.380 | -2.59% | 2,589,441 |
| 26-10-13 | US$3.470 | -3.61% | 3,439,350 |
| 26-10-12 | US$3.600 | -6.01% | 3,428,985 |
| 26-10-09 | US$3.830 | +1.06% | 5,060,059 |
| 26-10-08 | US$3.790 | +11.47% | 8,735,450 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ACRS Stock
Select your edition
All financial news and data tailored to specific country editions
